期刊
CROHNS & COLITIS 360
卷 1, 期 3, 页码 -出版社
OXFORD UNIV PRESS
DOI: 10.1093/crocol/otz026
关键词
biomarkers; Crohn disease; companion diagnostic; neutrophil CD64; pediatric
资金
- National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health (NIH) [K23 DK105229, K23 DK094832]
- Cincinnati Children's Research Foundation Trustee Award Program
- NIH (Gene Analysis Core) of the Digestive Disease Research Core Center in Cincinnati [P30 DK078392]
- Crohn's and Colitis Foundation PRO-KIIDS Award
Background: We hypothesized that elevations of plasma Oncostatin M (OSM) would be associated with infliximab nonresponse. Methods: Plasma OSM was measured in Crohn disease patients pre-infliximab with biochemical response (>50% reduction in fecal calprotectin) as the primary outcome. Results: The median OSM in biochemical responders was 86 (69-148) pg/mL compared with 166 (74-1766) pg/mL in nonresponders (P = 0.03). Plasma OSM > 143.5 pg/mL was 71% sensitive and 78% specific for biochemical nonresponse (area under the curve 0.71). Early biochemical nonremission was also associated with an elevated neutrophil CD64 expression (odds ratio 8.9, P = 0.011). Conclusions: Elevated preinfliximab plasma OSM and nCD64 surface expression were both associated with poor biochemical outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据